New patent for Sanofi-aventis Us drug SOLIQUA 100/33

Annual Drug Patent Expirations for SOLIQUA+100%2F33
Annual Drug Patent Expirations for SOLIQUA+100%2F33

Soliqua 100/33 is a drug marketed by Sanofi-aventis Us
and is included in one NDA. It is available from one supplier. There are seventeen patents protecting this drug.

This drug has two hundred patent family members in forty countries.

The generic ingredient in SOLIQUA 100/33 is insulin glargine; lixisenatide. One supplier is listed for this compound. Additional details are available on the insulin glargine; lixisenatide profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent for Supernus Pharms drug TROKENDI XR

Annual Drug Patent Expirations for TROKENDI+XR
Annual Drug Patent Expirations for TROKENDI+XR

Trokendi Xr is a drug marketed by Supernus Pharms
and is included in one NDA. It is available from one supplier. There are eight patents protecting this drug and two Paragraph IV challenges.

This drug has eleven patent family members in eight countries.

The generic ingredient in TROKENDI XR is topiramate. One supplier is listed for this compound. Additional details are available on the topiramate profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent for Sanofi Aventis drug APIDRA SOLOSTAR

Annual Drug Patent Expirations for APIDRA+SOLOSTAR
Annual Drug Patent Expirations for APIDRA+SOLOSTAR

Apidra Solostar is a drug marketed by Sanofi Aventis Us
and is included in one NDA. It is available from one supplier. There are eighteen patents protecting this drug.

This drug has two hundred and eleven patent family members in forty-three countries.

The generic ingredient in APIDRA SOLOSTAR is insulin glulisine recombinant. One supplier is listed for this compound. Additional details are available on the insulin glulisine recombinant profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent for Sanofi Aventis drug APIDRA

Annual Drug Patent Expirations for APIDRA
Annual Drug Patent Expirations for APIDRA

Apidra is a drug marketed by Sanofi Aventis Us
and is included in one NDA. It is available from one supplier. There are eighteen patents protecting this drug.

This drug has eigthy-one patent family members in thirty-nine countries.

The generic ingredient in APIDRA is insulin glulisine recombinant. One supplier is listed for this compound. Additional details are available on the insulin glulisine recombinant profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent for Sanofi Aventis drug LANTUS SOLOSTAR

Annual Drug Patent Expirations for LANTUS+SOLOSTAR
Annual Drug Patent Expirations for LANTUS+SOLOSTAR

Lantus Solostar is a drug marketed by Sanofi Aventis Us
and is included in one NDA. It is available from five suppliers. There are fourteen patents protecting this drug.

This drug has one hundred and thirty patent family members in twenty-six countries.

The generic ingredient in LANTUS SOLOSTAR is insulin glargine recombinant. Five suppliers are listed for this compound. Additional details are available on the insulin glargine recombinant profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent for Sanofi Aventis drug LANTUS

Annual Drug Patent Expirations for LANTUS
Annual Drug Patent Expirations for LANTUS

Lantus is a drug marketed by Sanofi Aventis Us
and is included in one NDA. It is available from five suppliers. There are seventeen patents protecting this drug.

The generic ingredient in LANTUS is insulin glargine recombinant. Five suppliers are listed for this compound. Additional details are available on the insulin glargine recombinant profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent expiration for Msd Intl drug VYTORIN

Annual Drug Patent Expirations for VYTORIN
Annual Drug Patent Expirations for VYTORIN

Vytorin is a drug marketed by Msd Intl
and is included in one NDA. It is available from five suppliers. There are two patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in VYTORIN is ezetimibe; simvastatin. Five suppliers are listed for this compound. Additional details are available on the ezetimibe; simvastatin profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent expiration for Merck Sharp drug LIPTRUZET

Annual Drug Patent Expirations for LIPTRUZET
Annual Drug Patent Expirations for LIPTRUZET

Liptruzet is a drug marketed by Merck Sharp Dohme
and is included in one NDA. There are two patents protecting this drug.

The generic ingredient in LIPTRUZET is atorvastatin calcium; ezetimibe. Additional details are available on the atorvastatin calcium; ezetimibe profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent expiration for Msd Intl drug ZETIA

Annual Drug Patent Expirations for ZETIA
Annual Drug Patent Expirations for ZETIA

Zetia is a drug marketed by Msd Intl Gmbh
and is included in one NDA. It is available from eight suppliers. There are four patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in ZETIA is ezetimibe. Eight suppliers are listed for this compound. Additional details are available on the ezetimibe profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com